Branavan Umakanthan, DO
Cardiovascular Disease · Las Vegas, NVNPI 1649359043
Payments from drug & device makers
Across 783 payments — averaging $139.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$32K
- Shockwave Medical, Inc$25K
- Medtronic$19K
- Edwards Lifesciences$15K
- Abbott$4K
- Amgen$2K
- plus $13K from 49 others
What the payments were for
- Consulting fees$19,30018%
- Speaking & faculty fees$51,17547%
- Travel & lodging$7,1357%
- Food & beverage$31,43329%
- Education$1230%
- Gifts$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo$31,030
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$17,656
- Edwards SAPIEN 3 Transcatheter Heart Valve$13,950
- IN.PACT Admiral$7,452
- Vascular Lithotripsy$5,779
- HawkOne$4,876
- GENERAL - STRUCTURAL HEART$1,092
- PASCAL$859
- Mitra Clip system$827
- SYMPLICITY G3$662
- TRICLIP$611
- TurboHawk$582
- ASAHI PTCA Guide Wire$478
- Abre$425
- Quadra Assura CRT Defibrillator$418
- CoreValve Evolut$396
- ENDURANT IIS$395
- Repatha$358
- HD-IVUS$301
- Endurant$278
How this compares
$109,249 in reported general payments places this provider in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 236 | $278,788 |
| Repatha SureclickEvolocumab | 242 | $217,308 |
| EntrestoSacubitril/Valsartan | 97 | $123,679 |
| XareltoRivaroxaban | 103 | $119,472 |
| BrilintaTicagrelor | 58 | $49,397 |
| VascepaIcosapent Ethyl | 42 | $30,673 |
| JardianceEmpagliflozin | 30 | $29,763 |
| MultaqDronedarone Hcl | 14 | $29,319 |
| Praluent PenAlirocumab | 26 | $16,836 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $10,808 |
| Icosapent Ethyl | 12 | $7,053 |
| ClopidogrelClopidogrel Bisulfate | 234 | $3,359 |
| Prasugrel Hcl | 19 | $2,844 |
| Metoprolol Succinate | 157 | $2,504 |
| Rosuvastatin Calcium | 83 | $2,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $278,788236 claims |
| NovartisEntresto | $1,022 | $123,67997 claims |
| Johnson & JohnsonXarelto | $310 | $119,472103 claims |
| AstraZenecaBrilinta | $14 | $49,39758 claims |
| Sanofi-aventis U.S. LLCMultaq | $324 | $29,31914 claims |
| Esperion Therapeutics, Inc.Nexlizet | $47 | $10,80813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Ramprasad DandillayaLas Vegas$1.8M
- Chowdhury AhsanLas Vegas$1.4M
- Arjun GururajLas Vegas$399K
- Navid KazemiLas Vegas$156K
- Sanjay MalhotraLas Vegas$101K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Rafael ValenciaLas Vegas$52K
- Salvador BorromeoLas Vegas$45K
- William ReshLas Vegas$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.